Alnylam Pharmaceuticals, Inc. (VIE:ALNY)
Austria · Delayed Price · Currency is EUR | Market Cap | 27.90B -48.2% |
| Revenue (ttm) | 4.41B +56.2% |
| Net Income | 2.37B +3,401.9% |
| EPS | 17.40 +3,191.0% |
| Shares Out | n/a |
| PE Ratio | 11.62 |
| Forward PE | 17.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 203.50 |
| Previous Close | 202.90 |
| Day's Range | 200.90 - 203.50 |
| 52-Week Range | 193.55 - 225.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]
News
Alnylam: 340B rule change would ‘substantially reduce’ Medicare reimbursement
Alnylam (ALNY) said on its Q3 earnings call that the proposed CMS rule change that if finalized as proposed, would substantially reduce Medicare reimbursement for Part B medicines acquired through…
Alnylam selloff on payer restrictions overdone, says H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio attributes the post-earnings selloff in Alnylam (ALNY) to the quarterly filing highlighting Medicare Advantage step-therapy restrictions and potential disrupti...
Alnylam downgraded at Stifel on slowing growth, slower pipeline progress
As previously reported, Stifel downgraded Alnylam (ALNY) to Hold from Buy with a price target of $225, down from $318, following the company’s Q3 report. Near-term estimates for Amvuttra are…
Alnylam downgraded to Hold from Buy at Stifel
Stifel downgraded Alnylam (ALNY) to Hold from Buy with a price target of $225, down from $318.
Alnylam Phase 2 bleeding disorders data pushed out, says Jefferies
Jefferies notes that along with Q3 results, Alnylam (ALNY) issued “minor pipeline updates,” including a “slight push” to pipeline catalysts on bleeding and obesity. ALN-6400 for bleeding disorders Pha...
Alnylam sinks after delaying Phase 2 data release to 2027
Shares of Alnylam (ALNY) are moving lower after the company pushed out the timelines for its hereditary hemorrhagic telangiectasia data. Alnylam now expects to announce clinical data from the Phase…
Alnylam trading halted, volatility trading pause
09:35 EDT Alnylam (ALNY) trading halted, volatility trading pause
Alnylam Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 product revenue rose 52% YoY, led by TTR, while slower-than-planned demand conversion drove a cautious outlook. TRITON-CM enrollment expanded to 2,250; 340B policy and access changes remain key uncertainties.
Alnylam Pharmaceuticals Earnings release: Q3 2026
Alnylam Pharmaceuticals released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Alnylam Pharmaceuticals Quarterly report: Q3 2026
Alnylam Pharmaceuticals has published its Q3 2026 quarterly earnings report on October 29, 2026.
Alnylam Pharmaceuticals Slides: Q3 2026
Alnylam Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended Se...
Alnylam Pharmaceuticals Transcript: Investor update
Initial phase Ib data showed dose-dependent CSF HTT reductions of 60%-64% at month 3, with no reported dose-dependent signals in inflammation, neurofilament or ventricular volume. A pivotal placebo-controlled study is planned for 2027, pending regulatory alignment.
Alnylam Pharmaceuticals Slides: Investor update
Alnylam Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Alnylam reports ALN-HTT02 clinical trial results
Alnylam (ALNY) reported initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington’s disease, which will be developed und...
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, a...
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter endi...
Alnylam assumed with a Buy at UBS
UBS analyst Joon Lee assumed coverage of Alnylam (ALNY) with a Buy rating with a price target of $354, down from $550. The firm states that its bullish conviction is…
Alnylam price target lowered to $253 from $256 at Wells Fargo
Wells Fargo analyst Derek Archila lowered the firm’s price target on Alnylam (ALNY) to $253 from $256 and keeps an Equal Weight rating on the shares ahead of quarterly results.
Alnylam price target lowered to $320 from $340 at Citi
Citi lowered the firm’s price target on Alnylam (ALNY) to $320 from $340 and keeps a Buy rating on the shares ahead of the Q3 report. The firm cites reduced…
Alnylam price target lowered to $336 from $346 at BofA
BofA analyst Tazeen Ahmad lowered the firm’s price target on Alnylam (ALNY) to $336 from $346 and keeps a Buy rating on the shares as the firm has become “more…
Alnylam price target lowered to $345 from $350 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm’s price target on Alnylam (ALNY) to $345 from $350 and keeps an Outperform rating on the shares as part of a broader…
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Alnylam price target lowered to $369 from $375 at JPMorgan
JPMorgan analyst Jessica Fye lowered the firm’s price target on Alnylam (ALNY) to $369 from $375 and keeps an Overweight rating on the shares. The firm adjusted estimates for Amvuttra…